These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 11293907)

  • 21. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis.
    Ghesquières H; Berger F; Felman P; Callet-Bauchu E; Bryon PA; Traverse-Glehen A; Thieblemont C; Baseggio L; Michallet AS; Coiffier B; Salles G
    J Clin Oncol; 2006 Nov; 24(33):5234-41. PubMed ID: 17043351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays.
    Zinzani PL; Dirnhofer S; Sabattini E; Alinari L; Piccaluga PP; Stefoni V; Tani M; Musuraca G; Marchi E; Falini B; Baccarani M; Pileri SA
    Haematologica; 2005 Mar; 90(3):341-7. PubMed ID: 15749666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study.
    Linderoth J; Jerkeman M; Cavallin-Ståhl E; Kvaløy S; Torlakovic E;
    Clin Cancer Res; 2003 Feb; 9(2):722-8. PubMed ID: 12576441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of BACH2 expression in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group.
    Sakane-Ishikawa E; Nakatsuka S; Tomita Y; Fujita S; Nakamichi I; Takakuwa T; Sugiyama H; Fukuhara S; Hino M; Kanamaru A; Soma T; Tsukaguchi M; Igarashi K; Kanakura Y; Aozasa K;
    J Clin Oncol; 2005 Nov; 23(31):8012-7. PubMed ID: 16258099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.
    López-Guillermo A; Colomo L; Jiménez M; Bosch F; Villamor N; Arenillas L; Muntañola A; Montoto S; Giné E; Colomer D; Beà S; Campo E; Montserrat E
    J Clin Oncol; 2005 Apr; 23(12):2797-804. PubMed ID: 15728226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pediatric primary bone lymphoma-diffuse large B-cell lymphoma: morphologic and immunohistochemical characteristics of 10 cases.
    Zhao XF; Young KH; Frank D; Goradia A; Glotzbecker MP; Pan W; Kersun LS; Leahey A; Dormans JP; Choi JK
    Am J Clin Pathol; 2007 Jan; 127(1):47-54. PubMed ID: 17145622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The distinction between Burkitt lymphoma and diffuse large B-Cell lymphoma with c-myc rearrangement.
    Nakamura N; Nakamine H; Tamaru J; Nakamura S; Yoshino T; Ohshima K; Abe M
    Mod Pathol; 2002 Jul; 15(7):771-6. PubMed ID: 12118116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased expression of the bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B-cell lymphomas.
    Bai M; Agnantis NJ; Skyrlas A; Tsanou E; Kamina S; Galani V; Kanavaros P
    Mod Pathol; 2003 May; 16(5):471-80. PubMed ID: 12748254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma.
    Banham AH; Connors JM; Brown PJ; Cordell JL; Ott G; Sreenivasan G; Farinha P; Horsman DE; Gascoyne RD
    Clin Cancer Res; 2005 Feb; 11(3):1065-72. PubMed ID: 15709173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Germinal center and activated b-cell profiles separate Burkitt lymphoma and diffuse large B-cell lymphoma in AIDS and non-AIDS cases.
    Gormley RP; Madan R; Dulau AE; Xu D; Tamas EF; Bhattacharyya PK; LeValley A; Xue X; Kumar P; Sparano J; Ramesh KH; Pulijaal V; Cannizzaro L; Walsh D; Ioachim HL; Ratech H
    Am J Clin Pathol; 2005 Nov; 124(5):790-8. PubMed ID: 16203284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of Fas (CD95/APO-1) positivity in patients with primary nodal diffuse large B-cell lymphoma.
    Eser B; Sari I; Canoz O; Altuntas F; Cakmak E; Ozturk A; Ozkan M; Er O; Cetin M; Unal A
    Am J Hematol; 2006 May; 81(5):307-14. PubMed ID: 16628716
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cluster analysis of apoptosis-associated bcl2 family proteins in diffuse large B-cell lymphomas. Relations with the apoptotic index, the proliferation profile and the B-cell differentiation immunophenotypes.
    Bai M; Skyrlas A; Agnantis NJ; Kamina S; Kitsoulis P; Kanavaros P
    Anticancer Res; 2004; 24(5A):3081-8. PubMed ID: 15517919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of CD29 on lymphoma cells and/or CD36 on microvascular endothels correlates with high serum LDH level in diffuse large B-cell lymphomas (DLBCLs) and is frequent in de novo CD5-positive DLBCLs.
    Ueno S; Yamaguchi M; Kimura M; Odagiri H; Shiraki K; Uemoto S; Nakamura N; Zhang W; Shiku H; Kobayashi T
    Int J Oncol; 2005 Nov; 27(5):1241-6. PubMed ID: 16211218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Large-cell diffuse B-cell lymphoma: heterogenous origin and prognosis from the aspect of modern diagnosis].
    Soukup J; Krsková L; Mrhalová M; Kodet R; Campr V; Kubácková K; Trnĕný M
    Cas Lek Cesk; 2003; 142(7):417-22. PubMed ID: 14515445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes.
    Watanuki-Miyauchi R; Kojima Y; Tsurumi H; Hara T; Goto N; Kasahara S; Saio M; Moriwaki H; Takami T
    Pathol Int; 2005 Jun; 55(6):324-30. PubMed ID: 15943789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis.
    Ohshima K; Kawasaki C; Muta H; Muta K; Deyev V; Haraoka S; Suzumiya J; Podack ER; Kikuchi M
    Histopathology; 2001 Aug; 39(2):156-62. PubMed ID: 11493332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma.
    Colomo L; López-Guillermo A; Perales M; Rives S; Martínez A; Bosch F; Colomer D; Falini B; Montserrat E; Campo E
    Blood; 2003 Jan; 101(1):78-84. PubMed ID: 12393466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of immunoglobulin VH genes in CD10-positive diffuse large B-cell lymphoma.
    Hojo H; Kuze T; Nakamura N; Hashimoto Y; Sasaki Y; Sato M; Shirakawa A; Abe M
    Pathol Int; 2002 Sep; 52(9):586-94. PubMed ID: 12406188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary central nervous system lymphoma: immunohistochemical profile and prognostic significance.
    Raoux D; Duband S; Forest F; Trombert B; Chambonnière ML; Dumollard JM; Khaddage A; Gentil-Perret A; Péoc'h M
    Neuropathology; 2010 Jun; 30(3):232-40. PubMed ID: 19925562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.
    Yamaguchi M; Seto M; Okamoto M; Ichinohasama R; Nakamura N; Yoshino T; Suzumiya J; Murase T; Miura I; Akasaka T; Tamaru J; Suzuki R; Kagami Y; Hirano M; Morishima Y; Ueda R; Shiku H; Nakamura S
    Blood; 2002 Feb; 99(3):815-21. PubMed ID: 11806981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.